BMGL Regains Compliance With Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Basel Medical Group (Nasdaq: BMGL) reported that Nasdaq has confirmed the company has regained compliance with the Nasdaq minimum $1.00 bid price requirement. Nasdaq had previously notified Basel Medical Group on January 22, 2026 that its shares were below the $1.00 minimum for 30 consecutive business days. Nasdaq has now determined that from June 23, 2026 to July 7, 2026, the company’s ordinary shares closed at or above $1.00 per share, restoring compliance with Listing Rule 5550(a)(2).
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Bid price restored to $1.00+ for 10 consecutive business days, June 23–July 7, 2026
- Nasdaq compliance regained with Listing Rule 5550(a)(2) on minimum bid price
Negative
- Prior bid-price deficiency notice on January 22, 2026 after 30 consecutive days below $1.00
News Market Reaction – BMGL
On the day this news was published, BMGL declined 0.23%, reflecting a mild negative market reaction. This price movement removed approximately $22K from the company's valuation, bringing the market cap to $9.71M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 10 | Reverse share split | Negative | -8.0% | Announced 1-for-12 reverse split to address Nasdaq bid-price deficiency. |
| Mar 24 | Filing compliance notice | Positive | -7.3% | Nasdaq confirmed compliance with periodic filing rule after amended Form 20-F. |
| Jan 23 | Bid-price deficiency notice | Negative | -3.5% | Nasdaq notified company its 30-day closing bid fell below $1 minimum. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
BMGL has often traded lower around prior Nasdaq listing and compliance-related announcements.
Key Terms
minimum bid price rule regulatory
listing rules regulatory
listing rule 5550(a)(2) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Singapore, July 10, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today announced that it has received notification from Nasdaq that the Company has regained compliance with the Nasdaq minimum bid price rule. On January 22, 2026, Nasdaq notified the Company that its ordinary shares failed to maintain a minimum bid price of
About Basel Medical Group Ltd
Basel Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine, orthopedic procedures and surgery, as well as neurosurgical treatments, executive health screening services, occupational medicine, rehabilitation, mental and women’s health and general medical practices. Our operations are based in Singapore, with our clinics being located at Suntec City Mall, Macpherson Road, Toa Payoh, Margaret Drive, Tampines, Gateway East and Gleneagles Medical Centre. Over the last 20 years, our group has forged strong and lasting relationships with a wide corporation clientele, particularly those in the construction, marine and oil & gas industries, which underpin our robust business model. As an medical service provider in Singapore with a track record of over 20 years, we are well-positioned to ride the wave of growth opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations, rising income levels, increasing private insurance coverage, increasing expenditure on healthcare, growing sports participation rate and Singapore’s position as a premium destination for healthcare services in Asia. Our management and medical practitioner team comprises a roster of orthopedic and neurosurgery specialists, general practitioners, corporate finance and healthcare partnership specialists. Basel Medical Group Ltd serves as the holding company of our group and we conduct our operations through our operating subsidiaries based in Singapore. For more information, please visit the Company’s website: www.baselmedical.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, which involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.
Media Contact:
Basel Medical Group Ltd
+65 6291 9188
contact@baselmedical.com
www.baselmedical.com
